Heidelberg, Germany
November 9, 2001Launched
as a joint venture in 1997, BASF-LYNX Bioscience AG has unveiled
its new name as Axaron Bioscience AG.
This step reflects the Heidelberg-based biotech team’s
successful corporate development and highlights its new
entrepreneurial autonomy. Addressing media at the company’s
November 9 press conference in the Heidelberg Technology Park,
CEO Dr. Alfred Bach announced, "This upbeat development signals
Axaron’s launch into a promising future as one of the most
capable functional genomics enterprises in the industry." The
company’s founding companies are German-based BASF AG und
U.S.-based LYNX Therapeutics, Inc.
Axaron Bioscience AG has emerged from BASF-LYNX Bioscience
AG, which was formed as a joint venture between BASF AG and LYNX
Therapeutics, Inc. in 1997. Axaron’s mission is to integrate
scientific expertise and technological know-how in the field of
functional genomics in order to provide solutions that enhance
the quality of life. The company’s activities focus on those
areas with the highest benefits to customers, shareholders and
society as a whole. Axaron has initiated a variety of
genomics-based research programs aimed at accelerating drug
discovery, improving drug safety and enhancing sustainable
biological production processes. |
